Navigation Links
Sunesis Presents Data Supporting SNS-032's Potential Anticancer,Activity in Multiple Myeloma at the American Association for Cancer,Research Meeting

Results from Non-clinical Studies Confirm Mechanism of Action and Provide Guidance for Dosing

SOUTH SAN FRANCISCO, April 16, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presented non-clinical data demonstrating SNS-032's apoptotic activity in a multiple myeloma model. These data were presented today in a poster session during the Annual Meeting of the American Association for Cancer Research (AACR).

SNS-032, a selective and potent inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, is currently in a Phase 1 clinical trial for B-cell malignancies, including chronic lymphocytic leukemia, multiple myeloma and mantle cell lymphoma. Non-clinical studies were conducted by Sunesis evaluating SNS-032's mechanism of action and in vitro activity against human multiple myeloma cell line RPMI-8226. Acting through inhibition of CDKs 2, 7, and 9, SNS-032 blocks both the cell cycle and transcription to drive apoptosis, or programmed cell death, in multiple myeloma cells upon exposure for six hours. Researchers also noted that exposure to SNS-032 induced down regulation of key anti-apoptotic factors, cell survival proteins, and growth factors that drive the disease. These results confirm that inhibiting CDKs 2, 7 and 9 targets both unregulated cell proliferation and the microenvironment associated with multiple myeloma and support the dosing regimen currently in use in the company's Phase 1 B-cell malignancy clinical trial.

"Data presented today from our non-clinical study of SNS-032 in multiple myeloma cell lines support our hypothesis that targeted inhibition of CDKs 2, 7 and 9 triggers cell death in hematologic cancer," said Daniel C. Adelman, M.D., Senior Vice President, Research and Development. "In addition, these results provide a pharmacologic basis for the dosing regimen being used in our Phase 1 clinical study, and identify potential biomarkers for monitoring activity."

Data
'"/>




Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
8. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
9. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
10. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
11. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
Post Your Comments:
(Date:5/16/2008)...tCall/ -- Pulmo BioTech Inc. (OTC,Bulletin Board: ...and,purpose of its Phase I Human Trials with its P...nosis of Pulmonary Embolism and Pulmonary,Hyperten...BioTech subsidiary,PulmoScience Inc., and the tit...lmoBind for Molecular Imaging of the Pulmonary Cir...
(Date:5/16/2008).../ -- BioVex Inc, a biotechnology,company developin...us,disease, announced today that the abstract desc...cal trial of OncoVEX GM-CSF in advanced metastatic... of Clinical Oncology,(ASCO) website located at h...ch describes the data as of the submission date to...
(Date:5/16/2008).../ -- Veridex, LLC announced today that,its licensi... Holdings,(LabCorp), has commercially launched a n...new assay uses the biological specificity of ,DNA,...hylation of the gene,GST-Pi. Methylation is a modi...eridex is developing the methylation markers in th...
(Date:5/15/2008)...ewswire/ -- Eisai Corporation of North,America ann...stracts about,compounds in the company,s oncology ...gy research have been accepted for presentation at...f Clinical Oncology (ASCO),taking place in Chicag... abstracts on Eisai marketed products and,investig...
Breaking Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Are humans hardwired for fairness 3F 2924 1Are humans hardwired for fairness 3F 2924 2Kiwa and Huaxing Set Up Preparatory Team for New Joint venture Company 4650 1Kiwa and Huaxing Set Up Preparatory Team for New Joint venture Company 4650 2World first discovery could help treat life threatening tumors 17006 1World first discovery could help treat life threatening tumors 17006 2Celator 28R 29 Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations 1827 1Celator 28R 29 Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations 1827 2Celator 28R 29 Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations 1827 3
...aZeneca Focuses Research on Growing Childhood Cond...all/ -- AstraZeneca,will present several studies t...ageal reflux disease (GERD) during oral and poster...ting held at the,Washington Convention Center. , T...neca,s,commitment to research in the area of gastr...
...ene to Advance Clinical and Regulatory Development..., May 22, 2007 /PRNewswire-FirstCall/ -- Celgene,C...lopment of,leading oral anti-inflammatory candidat...CC-10004 (apremilast), an oral TNF,antagonist and ...nt,activity and an excellent side effect profile i...
Other Medicine Technology:New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At,Annual Digestive Disease Week Meeting 2New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At,Annual Digestive Disease Week Meeting 3New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At,Annual Digestive Disease Week Meeting 4New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At,Annual Digestive Disease Week Meeting 5Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral,Approach to Treating Inflammatory Diseases 2Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral,Approach to Treating Inflammatory Diseases 3Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral,Approach to Treating Inflammatory Diseases 4
(Date:5/16/2008)...Newswire/ -- Less than a week after,committing med...stated by,Cyclone Nargis, Project HOPE, an interna...e organization, is again mobilizing its full,resou...or the people of,central China devastated by the m...ives., "I am saddened by the vast loss of life an...
(Date:5/16/2008)...people who didn,t have cancer as children, study f... -- Adults who had cancer as children or teens are... a new study found. , And the heart problems s...d not suffer cancer as children. , Childhood ca...mes increased risk of having heart disease compare...
(Date:5/16/2008)...t The University of Texas M. D. Anderson Cancer Ce... leukemia cells by shutting down their energy sour...ical study, Lauren Akers, D.O., postdoctoral fello...erson, found that combining a novel glycolysis inh...duced more than 90 percent cell death in human tis...
(Date:5/16/2008)...hs School of Nursing and Midwifery, has won the In...an Nursing Awards. , Professor Rickard won top ... during testing procedures, reducing the risk of a...lready ill patients. The award was announced last ...inment complex. , Nurses routinely take blood s...
Breaking Medicine News(10 mins):Health News:Project HOPE to Send Humanitarian Assistance to China as Humanitarian Assistance to Myanmar Continues 2Health News:Childhood Cancer Survivors Prone to Early Heart Trouble 2Health News:Childhood Cancer Survivors Prone to Early Heart Trouble 3Health News:New drug combination brings 1-2 punch against acute leukemia 2Health News:Research talent wins national Innovation in Nursing award 2
...abad High Court today directed Uttar Pradesh gover...olleges in the state imparting education in Indian...t not to continue with counselling and admission p...he order was passed by Justice Sunil Ambawani on a...
... to a survey conducted by a charity organization i...f the people in UK are ignorant about the existenc...). The general public said that they have never ...-biggest killer disease as it affects 3 million pe...
... to the Auckland University School of Population h...s a sudden increase in the number of patients// wh... article that was published in the New Zealand Med...ess attitudes of the medical professionals led to ...
... to a study conducted by the researchers at the Un... diminishes the man's ability to think clearly.// ...lysed about eight unmarried, childless couples in ...r beds and on the next day they were asked to perf...
Other Medicine News:
...ntinuous low-flow nebulizer performance. Patented ...llows for optimal medication and Heliox delivery (...ere asthma, COPD and pneumonia in both routine and...mouth and T-piece to deliver high-output, low-flow...
...s., ,ACE ensures prompt, effective delivery of ae...tile design allows it to be used in a ventilator c... or resuscitation bag and for routine, oral inhala...incentive spirometer to help teach the patient pro...
...tion Mouthpiece 7FT O 2 Tubing Tee Adapter , ...provide maximum aerosol quality and respirable out...ent time. Each of these high-efficiency nebulizers...adapter for use with your ventilator applications....
Nebulizer Custom Kit
Medicine Products: